Cargando…

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertoli, Sarah, Sterin, Arthur, Tavitian, Suzanne, Oberic, Lucie, Ysebaert, Loïc, Bouabdallah, Reda, Vergez, François, Sarry, Audrey, Bérard, Emilie, Huguet, Françoise, Laurent, Guy, Prébet, Thomas, Vey, Norbert, Récher, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887/
https://www.ncbi.nlm.nih.gov/pubmed/27852053
http://dx.doi.org/10.18632/oncotarget.13262
_version_ 1782514549821276160
author Bertoli, Sarah
Sterin, Arthur
Tavitian, Suzanne
Oberic, Lucie
Ysebaert, Loïc
Bouabdallah, Reda
Vergez, François
Sarry, Audrey
Bérard, Emilie
Huguet, Françoise
Laurent, Guy
Prébet, Thomas
Vey, Norbert
Récher, Christian
author_facet Bertoli, Sarah
Sterin, Arthur
Tavitian, Suzanne
Oberic, Lucie
Ysebaert, Loïc
Bouabdallah, Reda
Vergez, François
Sarry, Audrey
Bérard, Emilie
Huguet, Françoise
Laurent, Guy
Prébet, Thomas
Vey, Norbert
Récher, Christian
author_sort Bertoli, Sarah
collection PubMed
description Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently.
format Online
Article
Text
id pubmed-5349887
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53498872017-04-06 Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies Bertoli, Sarah Sterin, Arthur Tavitian, Suzanne Oberic, Lucie Ysebaert, Loïc Bouabdallah, Reda Vergez, François Sarry, Audrey Bérard, Emilie Huguet, Françoise Laurent, Guy Prébet, Thomas Vey, Norbert Récher, Christian Oncotarget Research Paper Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently. Impact Journals LLC 2016-11-10 /pmc/articles/PMC5349887/ /pubmed/27852053 http://dx.doi.org/10.18632/oncotarget.13262 Text en Copyright: © 2016 Bertoli et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Bertoli, Sarah
Sterin, Arthur
Tavitian, Suzanne
Oberic, Lucie
Ysebaert, Loïc
Bouabdallah, Reda
Vergez, François
Sarry, Audrey
Bérard, Emilie
Huguet, Françoise
Laurent, Guy
Prébet, Thomas
Vey, Norbert
Récher, Christian
Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
title Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
title_full Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
title_fullStr Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
title_full_unstemmed Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
title_short Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
title_sort therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887/
https://www.ncbi.nlm.nih.gov/pubmed/27852053
http://dx.doi.org/10.18632/oncotarget.13262
work_keys_str_mv AT bertolisarah therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT sterinarthur therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT tavitiansuzanne therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT obericlucie therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT ysebaertloic therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT bouabdallahreda therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT vergezfrancois therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT sarryaudrey therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT berardemilie therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT huguetfrancoise therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT laurentguy therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT prebetthomas therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT veynorbert therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies
AT recherchristian therapyrelatedacutemyeloidleukemiafollowingtreatmentoflymphoidmalignancies